翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03378 翰思艾泰-B

交易中 04-09 14:42:27

30.820

+0.480

+1.58%

最高31.220	最低29.140	成交量5.68万
今开29.140	昨收30.340	日振幅6.86%
总市值41.98亿	流通市值41.98亿	总股本1.36亿
成交额173.04万	换手率0.04%	流通股本1.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":30.82,"timestamp":1775716531192,"preClose":30.34,"halted":0,"volume":56800,"delay":0,"changeRate":0.01582069874752803,"floatShares":136218830,"shares":136218830,"eps":-10.596109,"marketStatus":"交易中","change":0.48,"latestTime":"04-09 14:42:27","open":29.14,"high":31.22,"low":29.14,"amount":1730390,"amplitude":0.068556,"askPrice":30.9,"askSize":500,"bidPrice":30.32,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-1.065,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775722200000},"marketStatusCode":2,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":30.34,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.442099,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"厦门港务","latestPrice":11.57,"timestamp":1775716947000,"preClose":11.85,"halted":0,"volume":12956900,"delay":0,"premium":"+132.42"}},"requestUrl":"/m/hq/s/03378/tweets","defaultTab":"tweets","newsList":[{"id":"2625673946","title":"翰思艾泰-B(03378)4月8日耗资约131.96万港元回购4.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625673946","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625673946?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:02","pubTimestamp":1775649729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)公布，2026年4月8日耗资约131.96万港元回购4.14万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1173","BK1535","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148459078","title":"翰思艾泰-B回购4.14万股股份，总额约131.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148459078","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148459078?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:01","pubTimestamp":1775649719,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司（股票代码：03378）于2026年4月8日公告，基于此前董事会授权，于香港联交所场内回购4.14万股H股普通股，占该公司已发行股份（不包括库藏股）约0.03%。本次每股回购价介乎每股31港元至32.12港元，合计耗资约131.96万港元。\n本次回购后，公司已发行股份总数约为1.36亿股，库藏股数量增至8.5万股。购回授权的决议通过日期为2026年2月12日，可回购股份总数为1362.1883万股，截至目前公司累计回购8.5万股，占授权比例约0.0624%。公司方面同时确认已遵守相关上市规则及适用法律法规程序，本次公告由董事长兼执行董事张发明签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159745807","title":"翰思艾泰-B更新2026年3月股份变动月报表，小幅回购43,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1159745807","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159745807?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:21","pubTimestamp":1775643661,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年4月8日披露2026年3月股份变动月报表，报告期截至2026年3月31日。具体结构方面，已发行股份数量由上月底的136,218,830股减少至本月底的136,175,230股，同时新增43,600股库存股份。此次变动主要源自2026年3月31日以每股港币29.3293回购股份43,600股，并以库存方式持有，尚未注销。公告显示，公司未有新发行股份、未涉及任何股份期权或股权激励计划变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623582958","title":"翰思艾泰-B(03378)3月31日斥资127.88万港元回购4.36万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623582958","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623582958?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:25","pubTimestamp":1774963551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)发布公告，于2026年3月31日，该公司斥资127.88万港元回购4.36万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1161","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140487706","title":"翰思艾泰-B3月31日回购43,600股，涉资约127.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140487706","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140487706?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:21","pubTimestamp":1774963270,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年3月31日发布公告，披露当日于香港联交所场内回购43,600股，占当日已发行股本约0.032%。此次回购价介乎每股28.50港元至29.90港元，总金额为1,278,758港元。本次回购完成后，公司已发行股本为136,175,230股，另有43,600股列作库藏股，总股本仍为136,218,830股。公司此前于2026年2月12日获得股东大会回购授权，可回购股份总数为13,621,883股，截至本次回购后累计已回购43,600股。公告由董事长兼执行董事张发明签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814268","title":"翰思艾泰-B(03378)发布年度业绩 净亏损1.31亿元 同比扩大12.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814268","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814268?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:31","pubTimestamp":1774585900,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布截至2025年12月31日止财政年度全年业绩，集团其他收入及收益人民币1661.6万元，同比增长116.33%;研发开支8936.3万元，同比增加19.6%;净亏损1.31亿元，同比扩大12.46%。截至2025年12月31日，本公司已建立“临床阶段(3款)+IND批准阶段(1款)+临床前阶段(多款)”的阶梯式产品管线布局，其中肿瘤免疫双特异性抗体、OX40靶向ADC等核心资产具备全球FIC潜力，为本公司长期发展奠定坚实的产品基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"翰思艾泰-B(03378)发布年度业绩 净亏损1.31亿元 同比扩大12.46%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1173","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112113269","title":"翰思艾泰-B 2025年研发投入加大，亏损扩大但股东权益显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1112113269","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112113269?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:24","pubTimestamp":1774585448,"startTime":"0","endTime":"0","summary":"翰思艾泰-B在截至2025年12月31日止年度内，其他收入及收益由2024年度的人民币768.10万元增至1,661.60万元。受研发及管理投入增加等因素影响，年内亏损由1.17亿元扩大至1.31亿元，母公司普通股股东应占每股亏损则由人民币0.98元扩大至人民币1.11元。同期股东权益由2024年末的2.17亿元增至7.48亿元，显示公司股本与权益结构在报告期内获得明显提升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620096440","title":"翰思艾泰-B(03378.HK)拟3月27日举行董事会会议审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620096440","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620096440?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:27","pubTimestamp":1773739626,"startTime":"0","endTime":"0","summary":"格隆汇3月17日丨翰思艾泰-B(03378.HK)宣布，董事会会议将于2026年3月27日(星期五)举行，藉以考虑及批准公司及其附属公司截至2025年12月31日止的年度业绩及其发布，并考虑建议派发末期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260317/32075067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1535","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618589289","title":"翰思艾泰-B03月10日主力净流出22.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618589289","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618589289?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:15","pubTimestamp":1773130546,"startTime":"0","endTime":"0","summary":"03月10日, 翰思艾泰-B股价跌0.62%，报收17.69元，成交金额155.3万元，换手率0.07%，振幅6.57%，量比0.57。翰思艾泰-B今日主力资金净流出22.0万元，上一交易日主力净流出0万元。该股近5个交易日上涨1.49%，主力资金累计净流入82.3万元；近20日主力资金累计净流入197.8万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161852a6b4c7a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161852a6b4c7a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1161","BK1535","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614163051","title":"翰思艾泰-B02月25日主力净流出32.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614163051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614163051?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:15","pubTimestamp":1772007333,"startTime":"0","endTime":"0","summary":"02月25日, 翰思艾泰-B股价跌0.11%，报收18.00元，成交金额80.6万元，换手率0.03%，振幅4.83%，量比0.23。翰思艾泰-B今日主力资金净流出32.9万元，上一交易日主力净流入91.2万元。该股近5个交易日下跌3.65%，主力资金累计净流入131.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入303.4万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225161731a71d47b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225161731a71d47b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613634769","title":"厦门港务2025 年第三季度利润分配方案：拟向全体股东每10股派0.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613634769","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613634769?lang=zh_cn&edition=full","pubTime":"2026-02-24 11:53","pubTimestamp":1771905186,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨厦门港务(000905.SZ)公布2025年第三季度利润分配方案，根据公司的利润分配政策、实际的经营及现金流情况，为积极回报股东，在符合利润分配原则、保证公司正常经营和长远发展的前提下，公司 2025 年第三季度利润分配方案为：以 2025 年 9 月 30 日公司总股本741,809,597 股为基数，向全体股东每 10 股派 0.3 元(含税)，拟分配利润为22,254,287.91 元；公司 2025 年第三季度不进行资本公积转增股本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224115532a4c142ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224115532a4c142ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1161","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184892830","title":"翰思艾泰生物医药科技（03378）1月无新增发行 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184892830","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184892830?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:43","pubTimestamp":1770281000,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年2月5日发布2026年1月股份变动月报表。截至2026年1月31日，公司已发行股本总数为136,218,830股，注册股本为人民币13,621,883元，面值为每股人民币0.1元。本次报告期内未见新增发行、购回、注销或库藏股活动。公司表示，所有证券发行及其他事项均遵守相关上市规则及法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608614323","title":"翰思艾泰-B(03378)：HX111完成首例病人用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2608614323","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608614323?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:51","pubTimestamp":1770209487,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，公司已启动自主研发的候选药物HX111针对复发难治性淋巴瘤及实体瘤的Ⅰ期临床试验，已于近期顺利完成首例患者入组给药。HX111可高亲和、高特异性地结合肿瘤细胞表面的OX40分子，并能高效地经内吞作用进入肿瘤细胞后，由溶酶体蛋白酶裂解连接子，释放强效有效载荷，进而诱导肿瘤细胞凋亡。该领域目前仍处于早期探索阶段，HX111具备显著的先发优势，未来有望填补此类肿瘤治疗领域的空白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608436193","title":"翰思艾泰-B(03378)：肖婕妤由非执行董事获调任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2608436193","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608436193?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:47","pubTimestamp":1770209223,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，因工作调整，肖婕妤女士(肖女士)由非执行董事获调任为执行董事，自2026年2月8日起生效。于肖女士调任执行董事生效后，彼将不再担任审核委员会的成员，自2026年2月8日起生效。本公司已调任肖女士为其总部的主要联络人，负责维持与李先生的日常沟通。董事会进一步宣布，委任肖女士担任公司首席财务官、董事会秘书，自2026年2月8日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"翰思艾泰-B(03378)：肖婕妤由非执行董事获调任为执行董事","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378","BK1535","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606759279","title":"翰思艾泰-B01月27日主力净流入17.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2606759279","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606759279?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:15","pubTimestamp":1769501755,"startTime":"0","endTime":"0","summary":"01月27日, 翰思艾泰-B股价涨0.47%，报收17.05元，成交金额82.9万元，换手率0.04%，振幅2.30%，量比0.55。翰思艾泰-B今日主力资金净流入17.3万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.16%，主力资金累计净流入34.2万元；近20日主力资金累计净流出429.6万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127162304a6b22371&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127162304a6b22371&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606887262","title":"翰思艾泰-B：稳定价格期结束、无稳定价格行动及超额配股权失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2606887262","media":"新浪港股","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606887262?lang=zh_cn&edition=full","pubTime":"2026-01-26 09:12","pubTimestamp":1769389920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　翰思艾泰-B（03378）发布公告，有关全球发售的稳定价格期已于2026年1月17日（星期六）（即递交香港公开发售申请截止日期后第30日）结束。此外，保荐人兼整体协调人（为其本身及代表国际包销商）确认，国际发售项下发售股份并无超额分配。因此，超额配股权未获行使并已于2026年1月17日（星期六）失效。稳定价格操作人告知公司，稳定价格操作人或代其行事的任何人士于稳定价格期并无采取稳定价格行动。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-01-26/doc-inhiqsxi9274228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03378","BK1173","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605403681","title":"翰思艾泰-B(03378)：稳定价格期结束、无稳定价格行动及超额配股权失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2605403681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605403681?lang=zh_cn&edition=full","pubTime":"2026-01-23 21:53","pubTimestamp":1769176388,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)发布公告，有关全球发售的稳定价格期已于2026年1月17日(星期六)(即递交香港公开发售申请截止日期后第30日)结束。此外，保荐人兼整体协调人(为其本身及代表国际包销商)确认，国际发售项下发售股份并无超额分配。因此，超额配股权未获行使并已于2026年1月17日(星期六)失效。稳定价格操作人告知公司，稳定价格操作人或代其行事的任何人士于稳定价格期并无采取稳定价格行动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604132633","title":"翰思艾泰-B01月19日获主力加仓42.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604132633","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604132633?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:15","pubTimestamp":1768810523,"startTime":"0","endTime":"0","summary":"01月19日, 翰思艾泰-B股价涨1.29%，报收17.28元，成交金额371.2万元，换手率0.16%，振幅3.22%，量比1.67。翰思艾泰-B今日主力资金净流入42.2万元，上一交易日主力净流入16.9万元。该股近5个交易日上涨1.95%，主力资金累计净流出38.2万元；近20日主力资金累计净流出463.8万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119161736a72b8fc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119161736a72b8fc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603165921","title":"翰思艾泰重塑CD47赛道 引领肿瘤免疫治疗迈入黄金时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2603165921","media":"泡财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603165921?lang=zh_cn&edition=full","pubTime":"2026-01-13 18:35","pubTimestamp":1768300517,"startTime":"0","endTime":"0","summary":"翰思艾泰以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的单一框架，深度解码CD47在肿瘤免疫中的核心调控密码。两款重磅管线不仅有效攻克了传统CD47疗法的毒性痛点，更开辟了免疫检查点联合靶向的全新治疗路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2601193178","title":"厦门港务：拟61.78亿元购买集装箱码头集团70%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601193178","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601193178?lang=zh_cn&edition=full","pubTime":"2026-01-06 18:43","pubTimestamp":1767696203,"startTime":"0","endTime":"0","summary":"人民财讯1月6日电，厦门港务(000905)1月6日公告，拟发行股份及支付现金购买厦门国际港务有限公司（简称“国际港务”）持有的厦门集装箱码头集团有限公司（简称“集装箱码头集团”）70%股权。交易价格为61.78亿元，其中现金对价9.27亿元，股份对价52.51亿元。同时，拟向不超过35名特定对象募集配套资金不超过35亿元，用于厦门港多式联运智慧物流中心项目、码头设备更新改造项目、翔安港区1#—5#集装箱泊位工程项目、支付本次交易现金对价、补充流动资金等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106185622a6fa1cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106185622a6fa1cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hanxbio.com/","stockEarnings":[{"period":"1week","weight":-0.0548},{"period":"1month","weight":0.7045},{"period":"3month","weight":0.7953},{"period":"6month","weight":-0.0519},{"period":"ytd","weight":0.8986}],"compareEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0191},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.2864},{"period":"ytd","weight":0.0102}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰思艾泰生物医药科技（武汉）股份有限公司是一家主要从事肿瘤免疫疗法的研发的中国公司。该公司的产品管线有针对肿瘤学的临床阶段候选药物和临床前阶段候选药物，包括核心产品HX009及主要产品HX301及HX044，以及针对自身免疫和肿瘤市场的抗体偶联药物、双特异性抗体及单克隆抗体。HX009是一种自主研发的抗程序性细胞死亡蛋白1（PD-1）/信号调节蛋白α（SIRPα）双功能抗体融合蛋白。HX301是一种靶向集落刺激因子-1受体（CSF1R）、AMPK相关蛋白激酶5（ARK5）、FMS样酪氨酸激酶3（FLT-3）及细胞周期蛋白依赖性激酶4/6（CDK4/6）等关键通路的多靶点激酶抑制剂。HX044为一种新型双重功能抗细胞毒性T淋巴细胞相关蛋白4（CTLA-4）抗体SIRPα融合蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.005427},{"month":2,"riseRate":0.411765,"avgChangeRate":0.008835},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.021319},{"month":4,"riseRate":0.705882,"avgChangeRate":0.100651},{"month":5,"riseRate":0.352941,"avgChangeRate":0.046508},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.00883},{"month":7,"riseRate":0.470588,"avgChangeRate":0.004276},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.031033},{"month":9,"riseRate":0.588235,"avgChangeRate":-0.013577},{"month":10,"riseRate":0.75,"avgChangeRate":0.019136},{"month":11,"riseRate":0.625,"avgChangeRate":0.009468},{"month":12,"riseRate":0.625,"avgChangeRate":0.056179}],"exchange":"SEHK","name":"翰思艾泰-B","nameEN":"HANXBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰思艾泰-B,03378,翰思艾泰-B股票,翰思艾泰-B股票老虎,翰思艾泰-B股票老虎国际,翰思艾泰-B行情,翰思艾泰-B股票行情,翰思艾泰-B股价,翰思艾泰-B股市,翰思艾泰-B股票价格,翰思艾泰-B股票交易,翰思艾泰-B股票购买,翰思艾泰-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}